A Prospective Trial in Patients With Crohn's Disease in Remission and Having Irritable Bowel Syndrome-like Symptoms

Inclusion Criteria: * Male and female patients aged from 18 years to 75 years, * Long standing (\>3 months prior to V1) steroid-free clinical remission Crohn's disease according to clinical and biochemical assessments, * Clinical remission (according to the investigator), * Absence of inflammatory markers at V1, * Presence of IBS-like symptoms according to Rome IV criteria, * Likert scale ≥ 3 for abdominal pain at V0, * Patient with correct and complete reporting of the study questionnaires and scores during the run-in period (≥ 75% completion), * To continue all medication used in the last month before inclusion at the same dosage, * Anti-spasmodic, hypomotility agents, probiotics, prebiotics, bile-acid chelators, and anti-depressants are authorized if consumed for longer than 1 month before inclusion and maintained at a stable dosage for the entire study duration, * Agreeing to maintain their lifestyle behaviours during the participation in the study, * Patient has read, understood, and signed the informed consent form (ICF), * Patients capable of communicating with the investigator, replying to the questionnaires, and understanding the requirements and constraints of the study protocol, * Possession of a digital device (i.e., smartphone or tablet), * Patient willing to adhere to the study visit schedule and able to understand and comply with protocol requirements and product administration, * Male or female patient of childbearing potential who agrees to use acceptable methods of birth control (oral, transdermal, systemic contraception, intrauterine device, condom) for the duration of the study, * Patient can read and write in French. Exclusion Criteria: * Patients with other concomitant organic gastrointestinal abnormalities besides Crohn's disease: ano-perineal lesions, extra-intestinal manifestations of Crohn's disease, colorectal history of cancer or abdominal radiotherapy, symptomatic intestinal stenosis, substance dependence history, * Patients with significant comorbidities: instable cardiovascular diseases, complicated diabetes, instable thyroid function, * Patients receiving non-steroidal anti-inflammatory drugs, steroids, opioids, or narcotic analgesics in the last month before V0, * Patients beginning a diet or a specific treatment for functional symptoms (probiotics, prebiotics, anti spasmodic, chelators, anti-depressants, etc.) within one month before V1, * Ongoing antibiotics or antibiotics prescribed in the last 2 weeks before V1. * Excessive alcohol consumption (\>30 g/day \[i.e., 3 units/day\] for men and \>20 g/day \[i.e., 2 units/day\] for women) and/or drug abuse, * Pregnancy and lactation, or plan to become pregnant during the study period, * Participation in other studies involving investigational or marketed products concomitantly or less than 3 months prior to V0, * Known hypersensitivity to any of the ingredients or excipients of the study products, * Patient who has forfeited their freedom by administrative or legal award, or who is under guardianship or under limited judicial protection.